Kavar Capital Partners LLC Buys 705 Shares of Edwards Lifesciences Co. (NYSE:EW)

Share on StockTwits

Kavar Capital Partners LLC raised its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 9.2% in the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 8,390 shares of the medical research company’s stock after purchasing an additional 705 shares during the period. Kavar Capital Partners LLC’s holdings in Edwards Lifesciences were worth $670,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Altshuler Shaham Ltd purchased a new stake in shares of Edwards Lifesciences in the third quarter worth about $25,000. Savior LLC lifted its position in shares of Edwards Lifesciences by 243.6% in the second quarter. Savior LLC now owns 378 shares of the medical research company’s stock worth $26,000 after buying an additional 268 shares in the last quarter. Gemmer Asset Management LLC lifted its position in shares of Edwards Lifesciences by 205.6% in the second quarter. Gemmer Asset Management LLC now owns 382 shares of the medical research company’s stock worth $26,000 after buying an additional 257 shares in the last quarter. Sun Life Financial INC lifted its position in shares of Edwards Lifesciences by 206.6% in the second quarter. Sun Life Financial INC now owns 374 shares of the medical research company’s stock worth $26,000 after buying an additional 252 shares in the last quarter. Finally, JNBA Financial Advisors lifted its position in shares of Edwards Lifesciences by 200.0% in the second quarter. JNBA Financial Advisors now owns 450 shares of the medical research company’s stock worth $31,000 after buying an additional 300 shares in the last quarter. 79.70% of the stock is owned by hedge funds and other institutional investors.

In other news, VP Larry L. Wood sold 10,698 shares of the stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $85.09, for a total transaction of $910,292.82. Following the completion of the sale, the vice president now owns 374,181 shares in the company, valued at approximately $31,839,061.29. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, VP Robert W.A. Sellers sold 21,540 shares of the stock in a transaction on Thursday, August 27th. The shares were sold at an average price of $82.60, for a total value of $1,779,204.00. Following the sale, the vice president now owns 48,508 shares of the company’s stock, valued at approximately $4,006,760.80. The disclosure for this sale can be found here. Insiders have sold a total of 444,244 shares of company stock worth $36,078,923 in the last ninety days. Insiders own 1.48% of the company’s stock.

NYSE EW traded down $0.71 during midday trading on Friday, hitting $84.53. 2,794,802 shares of the company traded hands, compared to its average volume of 3,594,272. The company has a debt-to-equity ratio of 0.14, a current ratio of 3.52 and a quick ratio of 2.61. The company has a market cap of $52.68 billion, a PE ratio of 67.62, a price-to-earnings-growth ratio of 2.48 and a beta of 0.92. The company’s 50-day simple moving average is $80.32 and its 200-day simple moving average is $86.20. Edwards Lifesciences Co. has a 52 week low of $51.51 and a 52 week high of $88.00.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Wednesday, October 21st. The medical research company reported $0.51 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.45 by $0.06. Edwards Lifesciences had a return on equity of 29.00% and a net margin of 18.18%. On average, research analysts predict that Edwards Lifesciences Co. will post 1.91 earnings per share for the current year.

A number of equities research analysts recently commented on the company. SVB Leerink boosted their target price on Edwards Lifesciences from $95.00 to $100.00 and gave the stock an “outperform” rating in a research report on Monday, October 12th. Canaccord Genuity upped their price objective on Edwards Lifesciences from $86.00 to $89.00 and gave the company a “buy” rating in a research report on Friday, July 24th. Stifel Nicolaus upped their price objective on Edwards Lifesciences from $85.00 to $90.00 and gave the company a “buy” rating in a research report on Friday, July 24th. Jefferies Financial Group increased their price target on Edwards Lifesciences from $95.00 to $105.00 and gave the stock a “buy” rating in a report on Tuesday, October 27th. Finally, Credit Suisse Group increased their price target on Edwards Lifesciences from $92.00 to $97.00 and gave the stock an “outperform” rating in a report on Thursday, October 22nd. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating and fourteen have assigned a buy rating to the stock. Edwards Lifesciences has a consensus rating of “Buy” and an average target price of $87.16.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases.

Featured Article: Why is momentum important to successful trading?

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Co. (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.